The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,194,821 | -10,482,761 |
| Depreciation | 72,022 | 155,349 |
| Amortization | 13,675 | 15,789 |
| Amortization of right-of-use assets | 125,379 | 260,819 |
| Share-based compensation expense | 174,514 | 549,208 |
| Loss on property and equipment dispositions | 0 | -53,173 |
| Amortization of debt issuance costs and discount | 426,541 | 746,612 |
| Accounts receivable | 317,615 | -233,789 |
| Inventory | 551,236 | 2,186,415 |
| Prepaid and other assets | -118,326 | -165,056 |
| Accounts payable | -1,101,759 | 1,758,162 |
| Accrued expenses | -24,291 | -98,297 |
| Lease liabilities | -128,270 | -264,580 |
| Other liabilities | 160 | -23,854 |
| Net cash used in operating activities | -5,387,375 | -9,117,950 |
| Acquisition of patents | 45,483 | 2,733 |
| Purchases of property and equipment | 194,333 | 190,834 |
| Net cash used in investing activities | -239,816 | -193,567 |
| Proceeds from the issuance of common stock in june 2025 financing | - | 4,510,001 |
| Proceeds from the issuance of common stock-Warrants Eight | 4,510,001 | - |
| Issuance costs for june 2025 financing | - | 804,940 |
| Issuance costs-Warrants Eight | 804,940 | - |
| Proceeds from at-the-market sales of common stock | 0 | 5,496,791 |
| Issuance costs for at-the-market sales of common stock | 0 | 164,904 |
| Proceeds from common stock issued through espp | 0 | 40,875 |
| Proceeds from the issuance of common stock-Warrants Nine | 7,998,826 | - |
| Issuance costs-Warrants Nine | 930,132 | - |
| Proceeds from the exercise of pre-funded warrants | 429 | - |
| Repayment of note payable | 90,961 | - |
| Net cash provided by financing activities | 6,978,162 | 9,077,823 |
| Net change in cash and cash equivalents | 1,350,971 | -233,694 |
| Cash and cash equivalents at beginning of period | 3,451,761 | - |
| Cash and cash equivalents at end of period | 4,569,038 | - |
FEMASYS INC (FEMY)
FEMASYS INC (FEMY)